Brief: Lee's Pharmaceutical Receives FDA Approval Of Supplemental New Drug Application For Adasuve
27/01/2026 15:27
Jan 27 (Reuters) - Lee's Pharmaceutical Holdings Ltd 0950.HK: FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR ADASUVE Further company coverage: 0950.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA